Compare Abercrombie & Fitch Co. (ANF) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abercrombie & Fitch Co. vs DexCom, Inc. — how do they compare? Abercrombie & Fitch Co. trades at $92.43 (market cap $4.14B), while DexCom, Inc. trades at $75 (market cap $28.93B). The key difference: DexCom, Inc. is far larger — about 7× Abercrombie & Fitch Co.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ANF | DXCM | |
|---|---|---|
Market Cap | $4.14B | $28.93B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $89.53 |
52-Week Low | $65.61 | $54.84 |
Enterprise Value | $4.81B | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
